/CSTL
CSTL Stock - Castle Biosciences, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$39.44-0.40%
$0.16 (-0.40%) • Dec 19
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.74
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+26.8%upside
Target: $50.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CSTL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$39.05 – $39.83
TARGET (TP)$50.00
STOP LOSS$36.28
RISK/REWARD1:3.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.14
52W High$40.61
52W Low$14.59
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $332.07M | $219.79M | $137.04M | $94.08M | $62.65M |
| Gross Profit | $271.86M | $174.81M | $105.03M | $78.26M | $52.96M |
| Gross Margin | 81.9% | 79.5% | 76.6% | 83.2% | 84.5% |
| Operating Income | $8.67M | $-67,977,000 | $-72,855,000 | $-40,079,000 | $-6,542,000 |
| Net Income | $18.25M | $-57,466,000 | $-67,138,000 | $-31,292,000 | $-10,284,000 |
| Net Margin | 5.5% | -26.1% | -49.0% | -33.3% | -16.4% |
| EPS | $0.66 | $-2.14 | $-2.58 | $-1.24 | $-0.54 |
Company Overview
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$40
Average Target
↑ 0.2% Upside
Now
$25
Low
$40
Average
$54
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 14th 2023 | Guggenheim | Initiation | Buy | $25 |
| January 5th 2023 | Scotiabank | Initiation | Sector Outperform | $54 |
Earnings History & Surprises
CSTLBeat Rate
67%
Last 18 quarters
Avg Surprise
+95.3%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-0.02
Q4 2025
EPS Surprise History
Q1 24
+88.1%
$-0.10vs$-0.84
Q2 24
+75.7%
$-0.09vs$-0.37
Q3 24
+214.8%
$0.31vs$-0.27
Q4 24
+233.3%
$0.08vs$-0.06
Q1 25
+900.0%
$0.32vs$-0.04
Q2 25
-150.0%
$-0.20vs$-0.08
Q3 25
+129.4%
$0.15vs$-0.51
Q4 25
+94.1%
$-0.02vs$-0.34
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.28 | — | — | — |
Q4 2025 | Nov 3, 2025 | $-0.34 | $-0.02 | +94.1% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $-0.51 | $0.15 | +129.4% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $-0.08 | $-0.20 | -150.0% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.04 | $0.32 | +900.0% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $-0.06 | $0.08 | +233.3% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-0.27 | $0.31 | +214.8% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.37 | $-0.09 | +75.7% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.84 | $-0.10 | +88.1% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.92 | $-0.26 | +71.7% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-1.01 | $-0.70 | +30.7% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.80 | $-1.10 | -37.5% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-0.91 | $-0.78 | +14.3% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.70 | $-0.77 | -10.0% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.58 | $-0.06 | +89.7% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.67 | $-0.80 | -19.4% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.43 | $-0.25 | +41.9% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.35 | $-0.47 | -34.3% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.29 | $-0.34 | -17.2% | ✗ MISS |
Latest News
Castle Biosciences Study Finds Decisiondx-Um Plus Prame Outperforms Ngs Gene Mutation Analysis In Predicting Metastasis-Free And Overall Survival In Uveal Melanoma
📈 PositiveBenzinga•Dec 17, 2025, 12:07 PM
Castle Biosciences Says Systematic Review And Meta-Analysis In Journal Of Clinical Gastroenterology Finds TissueCypher Barrett's Esophagus Test Outperforms Pathology And Clinical Factors, With High-Risk Results Linked To 6.7x Higher Five-Year Progression To HGD Or Esophageal Adenocarcinoma
📈 PositiveBenzinga•Dec 12, 2025, 12:04 PM•Also:
BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $50
📈 PositiveBenzinga•Dec 12, 2025, 11:08 AM
Castle Biosciences Announces Publication Of Expert Consensus Paper Endorsing DecisionDx-Melanoma Test
📈 PositiveBenzinga•Dec 9, 2025, 12:22 PM
Castle Biosciences Says New Data Shows DecisionDx-Melanoma Accurately Identifies Patients With Under 5% Risk Of Sentinel Node Positivity, Supporting More Precise Biopsy Decisions
📈 PositiveBenzinga•Nov 14, 2025, 12:04 PM
SciBase And Castle Biosciences Strengthen Partnership With Expanded Manufacturing Autonomy And SEK 20M Loan Agreement
📈 PositiveBenzinga•Nov 7, 2025, 09:11 AM
BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $38
📈 PositiveBenzinga•Nov 5, 2025, 09:48 AM
Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $41
📈 PositiveBenzinga•Nov 4, 2025, 05:19 PM
Castle Biosciences Rolls Out AdvanceAD-Tx Gene Expression Profile Test To Guide Treatment For Moderate-to-severe Atopic Dermatitis
📈 PositiveBenzinga•Nov 3, 2025, 09:17 PM
Castle Biosciences Raises FY2025 Sales Guidance from $310.000M-$320.000M to $327.000M-$335.000M vs $317.599M Est
📈 PositiveBenzinga•Nov 3, 2025, 09:12 PM
Castle Biosciences Q3 Adj. EPS $(0.02) Beats $(0.52) Estimate, Sales $83.043M Beat $71.209M Estimate
📈 PositiveBenzinga•Nov 3, 2025, 09:11 PM
DecisionDx-Melanoma Validated Across Cutaneous Melanoma Subtypes In 13,560 Patients With Results To Be Presented By Castle Biosciences At Dermatology Conference
📈 PositiveBenzinga•Oct 24, 2025, 08:16 AM
Castle Biosciences Study Finds 15% of Barrett's Esophagus Patients Face Higher Cancer Risk Than Pathology Suggests
📉 NegativeBenzinga•Sep 9, 2025, 11:19 AM
Castle Biosciences Expands DecisionDx-SCC Test to Predict Local Recurrence in High-Risk Skin Cancer Patients
📈 PositiveBenzinga•Aug 25, 2025, 11:14 AM
Frequently Asked Questions about CSTL
What is CSTL's current stock price?
Castle Biosciences, Inc. (CSTL) is currently trading at $39.44 per share. The stock has moved -0.40% today.
What is the analyst price target for CSTL?
The average analyst price target for CSTL is $50.00, based on 1 analyst.
What sector is Castle Biosciences, Inc. in?
Castle Biosciences, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is CSTL's market cap?
Castle Biosciences, Inc. has a market capitalization of $1.15 billion, making it a small-cap company.
Does CSTL pay dividends?
No, Castle Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMN
AMN Healthcare Services, Inc.
$16.04
Mkt Cap: $0.6B
CDNA
CareDx, Inc
$19.45
Mkt Cap: $1.0B
DRIO
DarioHealth Corp.
$11.54
Mkt Cap: $0.1B
EMBC
Embecta Corp.
$11.75
Mkt Cap: $0.7B
EVH
Evolent Health, Inc.
$3.99
Mkt Cap: $0.5B
FLGT
Fulgent Genetics, Inc.
$27.61
Mkt Cap: $0.8B
GERN
Geron Corporation
$1.33
Mkt Cap: $0.8B
MYGN
Myriad Genetics, Inc.
$6.55
Mkt Cap: $0.6B
PSNL
Personalis, Inc.
$8.55
Mkt Cap: $0.8B
VIR
Vir Biotechnology, Inc.
$5.76
Mkt Cap: $0.8B
Explore stocks similar to CSTL for comparison